Free Trial

Rep. Jefferson Shreve Sells The Clorox Company (NYSE:CLX) Stock

Clorox logo with Consumer Staples background

Representative Jefferson Shreve (R-Indiana) recently sold shares of The Clorox Company NYSE: CLX. In a filing disclosed on May 08th, the Representative disclosed that they had sold between $15,001 and $50,000 in Clorox stock on April 11th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.

Representative Jefferson Shreve also recently made the following trade(s):

  • Purchased $50,001 - $100,000 in shares of Chipotle Mexican Grill NYSE: CMG on 4/17/2025.
  • Purchased $50,001 - $100,000 in shares of Applied Materials NASDAQ: AMAT on 4/17/2025.
  • Purchased $15,001 - $50,000 in shares of Caterpillar NYSE: CAT on 4/17/2025.
  • Sold $15,001 - $50,000 in shares of Lululemon Athletica NASDAQ: LULU on 4/17/2025.
  • Purchased $15,001 - $50,000 in shares of Western Digital NASDAQ: WDC on 4/17/2025.
  • Sold $15,001 - $50,000 in shares of Zoetis NYSE: ZTS on 4/17/2025.
  • Purchased $15,001 - $50,000 in shares of Stryker NYSE: SYK on 4/17/2025.
  • Purchased $15,001 - $50,000 in shares of NextEra Energy NYSE: NEE on 4/17/2025.
  • Purchased $15,001 - $50,000 in shares of CSX NASDAQ: CSX on 4/17/2025.
  • Purchased $15,001 - $50,000 in shares of Ross Stores NASDAQ: ROST on 4/17/2025.

Clorox Trading Up 0.9%

Shares of Clorox stock traded up $1.14 during trading on Thursday, hitting $134.55. The company's stock had a trading volume of 677,680 shares, compared to its average volume of 1,310,381. The company has a debt-to-equity ratio of 20.52, a current ratio of 0.94 and a quick ratio of 0.60. The Clorox Company has a 52 week low of $127.60 and a 52 week high of $171.37. The stock has a market cap of $16.58 billion, a price-to-earnings ratio of 36.77, a price-to-earnings-growth ratio of 2.62 and a beta of 0.60. The stock has a 50-day moving average price of $141.56 and a two-hundred day moving average price of $153.64.

Clorox (NYSE:CLX - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a return on equity of 316.87% and a net margin of 6.38%. The business had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.74 billion. During the same period in the prior year, the firm earned $1.71 EPS. The business's revenue for the quarter was down 8.0% compared to the same quarter last year. Equities research analysts anticipate that The Clorox Company will post 7.15 EPS for the current fiscal year.

Clorox Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, May 9th. Stockholders of record on Wednesday, April 23rd were issued a dividend of $1.22 per share. The ex-dividend date was Wednesday, April 23rd. This represents a $4.88 annualized dividend and a dividend yield of 3.63%. Clorox's dividend payout ratio (DPR) is presently 87.61%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on CLX. Wells Fargo & Company cut their price target on shares of Clorox from $145.00 to $142.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Barclays lowered their target price on shares of Clorox from $134.00 to $129.00 and set an "underweight" rating on the stock in a report on Wednesday, May 7th. Evercore ISI set a $140.00 price target on Clorox and gave the company an "underperform" rating in a research report on Tuesday, May 6th. DA Davidson decreased their price target on shares of Clorox from $171.00 to $169.00 and set a "neutral" rating for the company in a research note on Wednesday, February 5th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating for the company in a report on Tuesday, May 6th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $151.23.

View Our Latest Report on CLX

Institutional Investors Weigh In On Clorox

Institutional investors and hedge funds have recently modified their holdings of the stock. Franklin Resources Inc. raised its stake in Clorox by 10.4% in the third quarter. Franklin Resources Inc. now owns 135,225 shares of the company's stock worth $21,840,000 after buying an additional 12,776 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of Clorox by 6.9% during the third quarter. Principal Financial Group Inc. now owns 151,257 shares of the company's stock valued at $24,641,000 after buying an additional 9,720 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Clorox by 1.2% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 46,309 shares of the company's stock valued at $7,544,000 after buying an additional 532 shares during the last quarter. ST Germain D J Co. Inc. boosted its holdings in Clorox by 7.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 4,281 shares of the company's stock worth $695,000 after purchasing an additional 300 shares during the last quarter. Finally, Graypoint LLC boosted its holdings in Clorox by 9.5% in the fourth quarter. Graypoint LLC now owns 4,269 shares of the company's stock worth $693,000 after purchasing an additional 370 shares during the last quarter. 78.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Clorox news, Director Pierre R. Breber purchased 4,000 shares of the company's stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the purchase, the director now directly owns 4,000 shares of the company's stock, valued at $546,280. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.57% of the stock is currently owned by insiders.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election. Email editor@ballotpedia.org to notify us of updates to this biography. Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive. Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

About Clorox

(Get Free Report)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Further Reading

Should You Invest $1,000 in Clorox Right Now?

Before you consider Clorox, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clorox wasn't on the list.

While Clorox currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Dirt-Cheap Stocks in a Market That’s Getting Expensive
Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines